Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
| Autor: | Ralf-Dieter Hofheinz, Lenka Kellermann, Kirsten Merx, Oliver Lange, Manuel Barreto Miranda, Ulrich Mahlknecht, Michael Gonnermann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Article Subject medicine.medical_treatment Locally advanced MEDLINE Bioinformatics 03 medical and health sciences 0302 clinical medicine Trastuzumab Esophagogastric cancer Internal medicine medicine lcsh:RC799-869 Chemotherapy Her2 expression Hepatology Performance status business.industry Gastroenterology 030104 developmental biology 030220 oncology & carcinogenesis Cohort lcsh:Diseases of the digestive system. Gastroenterology business Research Article medicine.drug |
| Zdroj: | Gastroenterology Research and Practice Gastroenterology Research and Practice, Vol 2016 (2016) |
| ISSN: | 1687-6121 |
| DOI: | 10.1155/2016/1028505 |
| Popis: | We analysed trends over time in palliative first-line chemotherapy in patients with locally advanced or metastatic esophagogastric cancer. Special focus was on frequency and quality of HER2-testing and trends in drug use in combination with trastuzumab. Earlier published data about patients treated outside clinical studies showed a relatively low rate of HER2-testing and insufficient test quality. A total of 2,808 patients retrospectively documented in Therapiemonitor®from 2006 to 2013 were analysed regarding treatment intensity and trends in used drugs. Data on HER2-testing and therapies were analysed in two cohorts documented in 2010 and 2011 (1) compared to 2012 and 2013 (2). Treatment intensity increased: 49.3% of patients received at least a triplet in 2013 compared to 10.1% in 2006. In cohort 2 HER2 expression was tested in 79.1% of the cases. Still, in 26.9% testing was not done as requested by guidelines. Good performance status, multiple metastases, age ≤ 65 years, the objective “to prevent progression,” good cognitive capabilities, estimated good compliance, and social integration positively influenced the probability of HER2-testing; comorbidities negatively affected it. Usage of the combination of fluoropyrimidines and cisplatin with trastuzumab declined from 67% in cohort 1 to 50% in cohort 2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|